The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

In the summer of 2015, the Ice Bucket Challenge stormed the internet. Social media was flooded with videos of people dumping ...

A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the ...

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

ALS groups ask lawmakers to preserve federal funding for the National ALS Registry, saying a draft budget memo proposes ...

CHENNAI: It’s nothing but the dance of mind and machine, where neurons whisper secrets and wires weave dreams. As the digital ...

ALS patient Bradford Smith became the third patient to test Neuralink — and the first one to do so who had lost the ability ...

Reduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Surprisingly, the protein shortage ...

For ALS Awareness Month this year, advocates want to raise the profile of the neurodegenerative disease in support of care, ...